Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance

• Tomohiro ItoBoehringer Ingelheim (Japan)
• Yusuke NaitoBoehringer Ingelheim (Japan)
• Naoki ShimmotoBoehringer Ingelheim (Japan)
• Kaori Ochiai
• Naoyuki HayashiBoehringer Ingelheim (Japan)
• Tomoo OkamuraBoehringer Ingelheim (Japan)